Skip to main content

Table 1 Baseline demographics and clinical characteristics for employed vs. not employed patients (patient subpopulation <65 years old)

From: Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment

 

Employed (n = 431)

Not employed (n = 276)

Total (n = 707)

Age, years

43.6 (9.4)*

47.4 (10.9)

45.1 (10.2)

Gender, male, n (%)

321 (74.5)

133 (48.2)

454 (64.2)

Race, White, n (%)

386 (89.6)

238 (86.2)

624 (88.3)

Body mass index

27.7 (5.2)

28.3 (5.9)

28.0 (5.5)

Psoriasis disease duration, years

18.0 (10.2)

19.1 (12.6)

18.4 (11.2)

PsA disease duration, years

6.7 (6.7)

7.5 (7.5)

7.0 (7.0)

Physician Psoriasis Assessment (scale: 0–5; higher scores = worse psoriasis)

3.6 (0.6)*

3.7 (0.7)

3.6 (0.7)

PASI (scale: 0–72; higher scores = worse psoriasis)

18.5 (9.5)*

21.4 (11.1)

19.6 (10.3)

BSA affected, %

28.7 (21.4)*

34.7 (23.6)

31.0 (22.5)

PGA of arthritis (scale: 0–100; higher scores = worse arthritis)

48.9 (20.4)*

53.2 (21.5)

50.6 (20.9)

Swollen joints (0–68)

11.4 (13.9)*

14.5 (16.8)

12.6 (15.2)

Tender joints (0–72)

17.6 (16.8)*

22.0 (19.1)

19.4 (17.9)

DLQI, total (scale: 0–30; higher scores = worse dermatology-related quality of life)

11.6 (7.3)*

13.8 (7.7)

12.5 (7.3)

EQ-5D Utility (scale: 0–1; higher scores = better quality of life), mean

0.55 (0.28)*

0.38 (0.35)

0.48 (0.32)

EQ-5D VAS (scale: 1–100; higher scores = better health), mean

58.0 (20.7)*

51.9 (20.6)

55.6 (20.9)

HAQ DI (scale: 0–3; higher scores = more disability), mean

0.72 (0.59)*

1.20 (0.75)

0.91 (0.69)

  1. *p < 0.01, for employed vs. not employed, one-way analysis of variance; p < 0.01, for employed vs. not employed, Fisher's Exact Test p-value (2-tail).
  2. Mean (SD), unless otherwise noted.